July 19, 2017 /
Click here to receive MS news via e-mail
Written by Ed Tobias
I used Ampyra for a few years and I thought it helped my walking, increasing my speed and stability a bit. So, I’m not surprised that this study reports benefits that I’d expect would follow an improvement of MS systems. But, be aware that this study was paid for by Acorda Therapeutics, the manufacturer of Ampyra.
A recent study has found that continued use of Ampyra (dalfampridine extended-release, sold in the U.S. by Acorda Therapeutics) by patients with multiple sclerosis (MS) lowers both inpatient hospital visits and overall healthcare costs.
Specifically, the authors reported that persistent use of Ampyra was associated with a 3.3% probability of hospital admission compared to 6.4% in patients with non-persistent use.
MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services.
Join us, opt-in here: www.register.msviewsandnews.org
…………………………
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
